FRPT Freshpet, Inc. Insider Trading

CEO Cyr sells 46,814 shares for $2,389,428.87 via 5 transactions on 2026-05-22 under 10b5-1 plan

William B. Cyr, CEO of Freshpet, executed 5 separate sales totaling 46,814 shares for $2,389,428.87 at an average price of $51.04 on 2026-05-22, reducing his non-derivative holdings from 102,935 shares to 56,121 shares. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, making it scheduled rather than discretionary. While the current price of $52.33 is -39.4% from the 52-week high and down -20.0% over 30 days, the insider's cross-ticker track record shows 19 prior sells with an average 90-day return of +3.2%, though his prior five trades at FRPT (all on 2026-05-18) averaged positive subsequent returns. Notably, the CEO retains derivative holdings representing option positions across four ownership vehicles, indicating his long-term economic exposure to the company remains significant despite the non-derivative share reduction.

CEO Cyr sells 47,582 shares for $2.3M at blended average $47.88 via pre-arranged 10b5-1 plan

William B. Cyr, Chief Executive Officer, executed 4 separate sales totaling 47,582 shares for $2,278,259.44 on 2026-05-20 under a 10b5-1 trading plan adopted on 2025-11-05. This transaction reduced his holdings by 48.9%, from 97,315 shares to 49,733 shares post-transaction. While the sale occurred at a blended average price of $47.88, the stock now trades at $51.58 current price, and the company shows solid fundamentals (P/E of 12.64, 13.0% annual revenue growth, and $48.5M net income on $297.6M quarterly revenue). His prior trades at FRPT (5 sales on 2026-05-18) all closed with positive returns: 90-day returns ranged from flat to 5.9%. Because this sale was scheduled under a pre-arranged 10b5-1 plan, it represents a committed trade sequence unrelated to discretionary timing judgment.

Director Daryl G Brewster bought 211 shares of FRPT at $47.52; stock now at $51.58, -42.6% from 52-week high. Cluster: 4 other insiders bought in past 14 days.

Director Daryl G Brewster purchased 211 shares at $47.52, increasing his holdings to 59,545 shares. This transaction occurs within a cluster pattern: 4 other insiders also bought FRPT within the past 14 days, suggesting coordinated buying activity at a depressed price point. The stock is currently trading 42.6% below its 52-week high of $89.80 and down 30.8% over 90 days, representing a substantial drawdown from recent peaks. At fundamentals (P/E of 12.64, 13.0% annual revenue growth, $48.5M net income), the valuation has compressed significantly relative to historical levels, which may explain the cluster activity. Brewster's prior two trades at FRPT show mixed timing: the September 2025 buy generated a +13.4% 90-day return, while the February 2025 buy resulted in a -19.5% 90-day return, illustrating inconsistent success in timing entry points at this ticker.

Director Steeneck bought 2,000 shares of FRPT at $47.83 (now $51.58, -42.6% from 52-week high); cluster of 5 other insiders buying within 14 days.

Craig D. Steeneck, a Director, purchased 2,000 shares at $47.83, increasing his holdings to 37,500 shares (+5.6%). The purchase occurs within a cluster pattern: 5 other insiders also bought FRPT within the past 14 days, suggesting coordinated sentiment at the board or management level. However, the stock's recent momentum is negative: -21.8% over 30 days and -30.8% over 90 days, and Steeneck's own prior buy at this ticker (on 2025-02-24) generated a -20.5% 90-day return, indicating his prior FRPT purchase did not prove well-timed. The company's fundamentals remain solid—$297.6M quarterly revenue with +13.0% annual growth and a 12.64 P/E—but the recent price decline and insider's poor timing history at this specific ticker warrant close attention to whether the cluster buy reflects conviction or other factors.

Director Timothy R McLevish bought 3,000 shares of FRPT at $48.67 on 2026-05-18; stock down -47.2% from 52-week high, cluster buy pattern detected.

Timothy R McLevish, a Director, purchased 3,000 shares at $48.67, increasing his holdings from 36,879 to 39,879 shares (+8.1%). The purchase occurs as FRPT trades at $47.39 current price, down -31.8% in 30 days and -35.1% in 90 days from purchase, positioning the stock -47.2% below its 52-week high of $89.80. His cross-ticker track record shows 8 prior open-market buys with a 12.50% 90-day win rate and average 90-day return of -13.1%; his same-ticker history at FRPT is mixed, with only 1 of 5 prior buys showing a positive 90-day return (+15.4% on the 2025-09-10 purchase), while the other four posted losses ranging from -9.1% to -20.8%. Fundamentals remain solid: $297.6M quarterly revenue with +13.0% annual growth and a P/E of 11.62. A cluster buy pattern is present, with 2 other insiders also purchasing within the past 14 days, though this does not explain the director's specific motivation.

Director Biegger David bought 1,000 shares at blended avg $49.14; now holds 8,488 shares. Stock down 47.2% from 52-week high; cluster pattern with 3 other insiders buying in past 14 days.

Director David Biegger executed 3 separate purchases totaling 1,000 shares for $49,142.30 on 2026-05-18, increasing his holdings by 13.4% to 8,488 shares. The timing coincides with significant price pressure: the stock has declined 47.2% from its 52-week high of $89.80 and is down 31.8% over the past 30 days and 35.1% over 90 days. His prior buy at FRPT on 2025-02-24 posted negative returns at both 30-day (-20.6%) and 90-day (-21.4%) intervals, establishing a pattern of unfavorable entry timing at this ticker. However, the simultaneous buying activity by 3 other insiders within the past 14 days creates a cluster pattern that may indicate internal assessment of valuation opportunity, though the company's fundamentals remain solid with $297.6M revenue, $48.5M net income, and 13.0% annual revenue growth. The convergence of steep price declines, repeated insider buying, and maintained financial performance warrants attention to whether this represents a bottom-fishing pattern or whether further deterioration is anticipated.

Director Kelley buys 1,000 FRPT shares at $48.05; stock down -47.2% from 52-week high of $89.80

Kelley Jacki Sue, a director of Freshpet, purchased 1,000 shares at $48.05 on 2026-05-18, a modest addition that increases her holdings by 7.4% to 14,496 shares post-transaction. The transaction occurs with the stock trading 47.2% below its 52-week high of $89.80 and down 31.8% over the prior 30 days, suggesting a purchase into significant recent weakness. Her prior buy at FRPT on 2025-09-09 achieved a 90-day return of +11.8%, a well-timed outcome on the same ticker. Underlying fundamentals remain solid: the company reported $297.6M quarterly revenue, net income of $48.5M, 13.0% annual revenue growth, and a P/E of 11.62, indicating operational strength despite recent price pressure. The purchase reflects confidence from a board member despite short-term momentum headwinds.

CEO Cyr sells 94,364 shares ($4.6M) via scheduled 10b5-1 plan; stock down -31.8% in 30 days, -47.2% from 52-week high

William B. Cyr, CEO of Freshpet, executed 13 separate sales totaling 94,364 shares for $4,638,364.50 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, reducing his holdings by 68.5% from 137,841 to 43,477 shares. The sales occurred across two trading dates (2026-05-15 and 2026-05-18) at a blended average price of $49.15, while the current stock price stands at $47.39—a 31.8% decline over the past 30 days and 47.2% below the 52-week high of $89.80. The company's fundamentals remain solid with FY revenue growth of 13.0%, a P/E of 11.62, and latest-quarter net income of $48,508,000.00, but the timing of this large liquidation by the chief executive against a backdrop of significant recent stock deterioration warrants investor attention to whether near-term operational headwinds prompted the plan's adoption or whether price weakness emerged after plan scheduling.

CEO Cyr sells 46,818 shares for $2,293,056.36 via scheduled 10b5-1 plan; stock down 28.3% in 30 days.

William B. Cyr executed 11 separate sales totaling 46,818 shares for $2,293,056.36 on 2026-05-13 under a pre-arranged 10b5-1 trading plan adopted 2025-11-05, reducing his holding from 77,646 shares to 30,828 shares. The stock has declined 28.3% over the past 30 days and is down 45.0% from its 52-week high of $89.80, trading at $49.35 versus transaction prices ranging from $10.23 to $51.07. Because this sale is part of a scheduled 10b5-1 plan, execution timing was predetermined and not discretionary. The insider's cross-ticker track record shows 1 prior buy with an average 90-day return of -58.2% and a 0.00% win rate, providing limited historical context for assessing this equity sales decision.

CEO Cyr exercises $859K in stock while selling $2.36M as stock trades well below 52-week highs.

CEO William B. Cyr exercised stock options worth $859K and immediately sold approximately half of his total holdings for $2.36M on the same day, netting a gain of roughly $37,500 shares while taking profits on the larger portion at prices well above his exercise price. The stock is trading roughly 46% below its 52-week high and has declined significantly over the past quarter, creating a disconnect: while Cyr expanded his net position, the scale of simultaneous selling suggests liquidity management rather than conviction. Freshpet remains profitable with solid revenue growth, but the CEO's hedging behavior—exercising equity compensation while aggressively diversifying exposure—suggests he is managing personal capital risk despite the company's operational strength. This is Cyr's first round of open-market sales at Freshpet in three years, making the volume and timing noteworthy.